UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For Quarterly Period Ended: March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-40681 Worksport Ltd. (Exact Name of Small Business Issuer as specified in its charter) | Nevada | 35-2696895 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 001-32288 NEPHROS, INC. (Exact name of registrant as specified in its charter) DELAWARE 13-3971809 (State or other jurisdiction of ...

Sales Performance - The Company reported a decrease in sales for EWCP products and TPA products due to decreased customer orders, with specific revenue figures of $830,483 for Company A and $1,856,395 for Company B in Q1 2025 compared to $1,291,426 and $2,299,938 in Q1 2024 respectively[76][79]. - Three primary customers accounted for 49% of the Company's sales in Q1 2025, down from 55% in Q1 2024, indicating a diversification in customer base[78]. Financial Performance - Gross profit decreased due to an increase in tariffs, while professional fees increased due to higher accounting and audit fees related to the Company's growth[76]. - Interest expense increased due to higher debt levels, impacting overall financial performance[76]. - The Company experienced a cash outflow of $544,294 from operating activities in Q1 2025, an improvement from $604,819 in Q1 2024[81]. Working Capital and Cash Flow - The Company’s working capital as of March 31, 2025, was $22,796,690, showing a slight increase from $22,714,190 as of December 31, 2024[81]. - The Company has sufficient cash resources to meet future commitments and cash flow requirements for the coming year[81]. Future Outlook - The Company anticipates no significant capital requirements for the twelve months ending March 31, 2026, indicating stable financial planning[82]. - New tariffs on raw materials imported from China are expected to affect future operating results, particularly in relation to aspartic acid used in TPA products[80]. Internal Controls - The Company implemented new procedures to improve financial reporting controls after identifying material weaknesses in the previous year[86].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 14, 2025 PRECIPIO, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36439 91-1789357 (State of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 4 Science Park, New Haven, CT 06511 (Address of principal executive of ices) (Zip Code) (203) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ______ to _______. Commission file number: 001-42507 Aureus Greenway Holdings Inc. (Exact name of registrant as specified in its charter) Nevada 99-0418678 ( ...

Business Acquisition and Product Development - Safety Shot Inc. completed the asset purchase of the Sure Shot Dietary Supplement in August 2023, gaining ownership of various assets including intellectual property and trademarks [124]. - The Sure Shot Dietary Supplement is formulated to reduce blood alcohol content and contains 28 active ingredients classified as Generally Regarded As Safe (GRAS) [125]. - The product was launched in December 2023 through the company's website, Amazon, and several Big Box stores, with plans for new flavors and formats [128]. - The Company owns five patents related to the Sure Shot Dietary Supplement, with the most recent patent expiring on November 5, 2035 [149]. - All ingredients in the Sure Shot Dietary Supplement are deemed Generally Recognized as Safe (GRAS) and comply with FDA standards [155]. - The Company is committed to continuous innovation and has built a substantial portfolio of intellectual property to address unmet market needs [135]. Financial Performance - The Company reported a net loss of $5,326,933 for the three months ended March 31, 2025, compared to a net loss of $15,674,671 for the same period in 2024 [165]. - The Company generated $42,101 in revenues for the three months ended March 31, 2025, a decrease of 75.3% compared to $170,732 in the same period of 2024 [187]. - Cost of sales for the three months ended March 31, 2025 was $21,112, significantly lower than $2,383,285 for the same period in 2024 [186]. - Total operating expenses decreased to $5,411,325 for the three months ended March 31, 2025, compared to $12,956,552 for the same period in 2024, reflecting a reduction of approximately 58% [188]. - The Company incurred research and development expenses of $9,005 for the three months ended March 31, 2025, down from $141,493 in the same period of 2024 [176]. - Stock-based compensation for the three months ended March 31, 2025 was $1,985,376, a significant decrease from $8,090,534 in the same period of 2024 [189]. - The Company reported other income of $63,402 for the three months ended March 31, 2025, compared to an expense of $505,566 in the same period of 2024 [186]. - Net loss for the three months ended March 31, 2025 was $5,326,933, a reduction of 66% compared to a net loss of $15,674,671 for the same period in 2024 [193]. Research and Development - Research and development expenses increased from $100,591 in 2022 to $1,637,117 in 2023, reflecting ongoing efforts to enhance existing products and develop new therapeutic options [132]. - Clinical trials conducted from January 29, 2024, to June 10, 2024, showed a statistically significant reduction in Blood Alcohol Content (BAC) with a p-value of 0.002 [131]. Regulatory and Compliance - The Company is subject to various U.S. federal, state, and local regulations affecting the production and sale of its dietary supplement products [150]. - The Company is classified as an "emerging growth company," allowing it to take advantage of certain exemptions from reporting requirements [160]. Investment and Financing - A settlement agreement with Bigger Capital was reached on January 20, 2025, involving a payment of $375,000 and the issuance of convertible notes totaling $5.25 million [136]. - The Secured Convertible Bigger Note has a 9% annual interest rate and can be converted into shares of common stock at a conversion price of $0.5435 or the market price [137][139]. - The Company is engaged in a Liabilities Settlement Program with Silverback Capital Corporation, involving an initial claim amount of $14,580,395.73 [147]. Operational Strategy - The company primarily sells products through e-commerce platforms, focusing on customer experience and brand promotion to drive growth [133]. - Manufacturing is outsourced to contract manufacturers in India and the US, with products shipped to third-party warehouses for distribution [134]. - The Company redirected its focus on the acquisition of Yerbae Brands Inc. and plans to implement a new marketing strategy in the second quarter of 2025 [187]. Shareholder Information - The weighted-average number of common shares outstanding increased to 69,258,402 in Q1 2025 from 47,435,503 in Q1 2024 [165]. - Basic and diluted loss per share for Q1 2025 was $0.08, compared to $0.33 for Q1 2024 [166]. - The Company has not recorded any cash equivalents as of March 31, 2025, or December 31, 2024 [163]. - The Company utilizes the equity method for investments in unconsolidated affiliates, reporting profits and losses in its financial statements [157]. - Deferred tax assets as of March 31, 2025 were approximately $15,362,309, fully offset by a valuation allowance due to the lack of earnings history [175].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________to_____________ Commission File Number 001-39569 SAFETY SHOT, INC. (Exact name of registrant as specified in charter) Delaware 83-2455880 (State or o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number: 001-41808 SR Bancorp, Inc. (Exact Name of Registrant as Specified in its Charter) Maryland 92-2601722 (St ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-41266 CEA INDUSTRIES INC. (Exact name of registrant as specified in its charter) Nevada 27-3911608 (State or other jurisdiction of incorporation or organization) 385 South ...

U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File No. 001-37370 MY SIZE, INC. (Exact name of registrant as specified in its charter) FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Delaware 51-0394637 (State or other jurisdiction of incorporation or ...